Alamar Biosciences Closes $80 Million Series B

<p><span class&equals;"xn-location"><strong>FREMONT<&sol;strong> <&sol;span>&&num;8212&semi; Alamar Biosciences&comma; Inc&period;&comma; a precision proteomics company that brings both ultra-high sensitivity and massively parallel scale to proteomic analysis&comma; has closed an <span class&equals;"xn-money">&dollar;80 million<&sol;span> Series B financing round&comma; bringing its total funding to <span class&equals;"xn-money">&dollar;110 million<&sol;span>&period; The Series B financing round was led by Sherpa Healthcare Partners and included Morningside Ventures&comma; Samsara Biocapital&comma; and existing investors Qiming Venture Partners and Illumina Ventures&period;<&sol;p>&NewLine;<p>The new investment will accelerate the development of Alamar&&num;8217&semi;s proprietary proteomics platform&comma; which will be the most sensitive&comma; highly multiplexed&comma; and high dynamic range solution for life science research&comma; pharmaceutical development&comma; and diagnostics such as liquid biopsy&period; The platform leverages Next Generation Sequencing to bring the power of genomics to proteomics&comma; enabling the early detection of cancer and other diseases&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We are very pleased to have these top-tier investors supporting our next phase of development&period; They bring tremendous amount of expertise in life sciences and diagnostics&comma; which will be extremely valuable to us as we build the company&comma;&&num;8221&semi; said Dr&period; <span class&equals;"xn-person">Yuling Luo<&sol;span>&comma; Founder&comma; Chairman and CEO&period; &&num;8220&semi;Despite recent progress in the field&comma; there is still no technology that unites two essential goals in proteomics analysis&comma; namely the ability to go as deeply as possible to detect very low abundance proteins and the ability to profile thousands of proteins in a single sample&period; This capability will be critical for the discovery and measurement of many proteins in human plasma that are currently undetectable&period; Alamar&&num;8217&semi;s NULISA and Attobody platforms will help fill this void and will drive a new wave of innovations in research&comma; diagnostics&comma; and therapeutics&period;&&num;8221&semi;<&sol;p>&NewLine;<p>Alamar Biosciences was founded by Dr&period; Luo&comma; a technologist and serial entrepreneur who previously founded Advanced Cell Diagnostics &lpar;ACD&rpar;&comma; now a part of Bio-Techne&comma; and led it as President and CEO&period; At ACD he pioneered the field of spatial genomics together with Dr&period; <span class&equals;"xn-person">Xiao-Jun Ma<&sol;span> by inventing and successfully commercializing RNAscope&comma; the world&&num;8217&semi;s most sensitive RNA <i>in situ<&sol;i> detection technology&period; Recognizing a similar critical need for ultra-sensitive protein detection technology in proteomics&comma; Dr&period; Luo started Alamar Biosciences with Dr&period; <span class&equals;"xn-person">Steve Chen<&sol;span>&comma; who was also a co-founder of ACD&comma; and Dr&period; <span class&equals;"xn-person">Yiyuan Yin<&sol;span>&comma; a structural biologist with extensive antibody engineering expertise&period;<&sol;p>&NewLine;<p>The Alamar Biosciences team has applied their insights gained from developing single-molecule detection technologies and antibody engineering to create two technology platforms – NULISA<sup>™<&sol;sup> and Attobody<sup>™ <&sol;sup>&period; The combination of these ground-breaking platforms provides the unique ability to detect extremely low levels of protein biomarkers in human blood plasma&comma; and to do so in a high-plex format allowing for the measurement of thousands of protein targets in a single assay&comma; leading to a new generation of noninvasive precision diagnostics&period;<&sol;p>&NewLine;<p>&&num;8220&semi;Alamar has made great strides in developing its novel technologies&period; This financing will position Alamar to complete the development of its platform and will help position the company for its commercial launch&comma;&&num;8221&semi; said <span class&equals;"xn-person">Nick Naclerio<&sol;span>&comma; Founding Partner of Illumina Ventures&period;<&sol;p>&NewLine;<p>&&num;8220&semi;We are thrilled to partner with the Alamar team to fully develop their game-changing platform and provide researchers around the globe with the tools they need to unlock the full potential of proteomics&comma;&&num;8221&semi; commented <span class&equals;"xn-person">Darren Cai<&sol;span>&comma; Founder and Managing Partner of Sherpa Healthcare Partners&period;<&sol;p>&NewLine;